Roy Herbst, MD, PhD of Yale School of Medicine, New Haven, CT talks on the updated outcomes of the KEYNOTE-010 trial of pembrolizumab vs docetaxel for previously treated, PD-L1-expressing non-small cell lung cancer (NSCLC) (NCT01905657) presented at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark. Prof. Herbst explains that KEYNOTE-010 is an important study as it was the first to show the benefit of pembrolizumab over docetaxel in patient with PD-L1 positive lung cancer. An early analysis of results was presented at ESMO Singapore last year. He then outlines the more mature data that was presented at ESMO. The responses are durable and benefit is persevered over a longer period of time and no new toxicities were observed. He further explains that the biomarker used in KEYNOTE-010 is the same used in KEYNOTE-024 (NCT02142738), the frontline trial of pembrolizumab vs chemotherapy.